Subacute Annular Pustular Psoriasis with Flexural Accentuation: Dramatic Response to Risankizumab
DOI:
https://doi.org/10.2340/actadv.v105.adv-2025-0055Keywords:
Psoriasis, Annular pustular psoriasis, Risankizumab, Pustular psoriasisDownloads
References
Owczarczyk-Saczonek A, Znajewska-Pander A, Owczarek W, Maciejewska-Radomska A, Placek W. Clinicopathologic retrospective analysis of annular pustular psoriasis. Acta Dermatovenerol Alp Pannonica Adriat 2018; 27: 215–219. DOI: https://doi.org/10.15570/actaapa.2018.44
Yamanaka K, Okubo Y, Yasuda I, Saito N, Messina I, Morita A. Efficacy and safety of risankizumab in Japanese patients with generalized pustular psoriasis or erythrodermic psoriasis: Primary analysis and 180-week follow-up results from the phase 3, multicenter IMMSPIRE study. J Dermatol 2023; 50: 195–202. DOI: https://doi.org/10.1111/1346-8138.16667
Ruggiero A, Lauro W, Fabbrocini G, Miano C, Villani A, Marasca C. A case of recalcitrant circinate generalized (Lapière) psoriasis successfully treated with risankizumab. Case Rep Dermatol 2022; 14: 138–143. DOI: https://doi.org/10.1159/000523756
Vasudevan B, Das P, Bhatt S. Pustular psoriasis: A distinct aetiopathogenic and clinical entity. Indian J Dermatol Venereol Leprol 2023; 90: 19–29. DOI: https://doi.org/10.25259/IJDVL_542_2022
Song HS, Kim SJ, Park TI, Jang YH, Lee ES. Immunohistochemical comparison of IL-36 and the IL-23/Th17 axis of generalized pustular psoriasis and acute generalized exanthematous pustulosis. Ann Dermatol 2016; 28: 451–456. DOI: https://doi.org/10.5021/ad.2016.28.4.451
Published
How to Cite
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
